Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia
ABSTRACT Background Real‐world evidence for hypomethylating agent (HMA) + venetoclax 50 mg (VEN50) with voriconazole and posaconazole in acute myeloid leukemia (AML), is limited. Methods We evaluated outcomes of patients with newly‐diagnosed AML treated with HMA + VEN50 with either posaconazole (n =...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | eJHaem |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jha2.70049 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849419443963166720 |
|---|---|
| author | Kendall Diebold Devan Parker Sarah Worth Manuel Espinoza‐Gutarra Pankit Vachhani Kimo Bachiashvili Sravanti Rangaraju Razan Mohty Ravi Bhatia Omer Jamy |
| author_facet | Kendall Diebold Devan Parker Sarah Worth Manuel Espinoza‐Gutarra Pankit Vachhani Kimo Bachiashvili Sravanti Rangaraju Razan Mohty Ravi Bhatia Omer Jamy |
| author_sort | Kendall Diebold |
| collection | DOAJ |
| description | ABSTRACT Background Real‐world evidence for hypomethylating agent (HMA) + venetoclax 50 mg (VEN50) with voriconazole and posaconazole in acute myeloid leukemia (AML), is limited. Methods We evaluated outcomes of patients with newly‐diagnosed AML treated with HMA + VEN50 with either posaconazole (n = 23) or voriconazole (n = 95). Results We report that treatment with HMA + VEN50 with either azole elicits a response rate similar to that described in the VIALE‐A trial. Reducing the VEN dose to 50 mg with either strong CYP3A4 inhibitor did not compromise on the efficacy of the combination. Conclusion HMA + VEN50 with either posaconazole or voriconazole yields comparable responses to higher doses of VEN reported previously. Clinical trial registration The authors have confirmed clinical trial registration is not needed for this submission. |
| format | Article |
| id | doaj-art-e448f4b1d3974b69a05635b6508ee8aa |
| institution | Kabale University |
| issn | 2688-6146 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | eJHaem |
| spelling | doaj-art-e448f4b1d3974b69a05635b6508ee8aa2025-08-20T03:32:04ZengWileyeJHaem2688-61462025-06-0163n/an/a10.1002/jha2.70049Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid LeukemiaKendall Diebold0Devan Parker1Sarah Worth2Manuel Espinoza‐Gutarra3Pankit Vachhani4Kimo Bachiashvili5Sravanti Rangaraju6Razan Mohty7Ravi Bhatia8Omer Jamy9Division of Hematology and Oncology, Department of Medicine University of Alabama at Birmingham Birmingham Alabama USADivision of Hematology and Oncology, Department of Medicine University of Alabama at Birmingham Birmingham Alabama USADivision of Hematology and Oncology, Department of Medicine University of Alabama at Birmingham Birmingham Alabama USADivision of Hematology and Oncology, Department of Medicine University of Alabama at Birmingham Birmingham Alabama USADivision of Hematology and Oncology, Department of Medicine University of Alabama at Birmingham Birmingham Alabama USADivision of Hematology and Oncology, Department of Medicine University of Alabama at Birmingham Birmingham Alabama USADivision of Hematology and Oncology, Department of Medicine University of Alabama at Birmingham Birmingham Alabama USADivision of Hematology and Oncology, Department of Medicine University of Alabama at Birmingham Birmingham Alabama USADivision of Hematology and Oncology, Department of Medicine University of Alabama at Birmingham Birmingham Alabama USADivision of Hematology and Oncology, Department of Medicine University of Alabama at Birmingham Birmingham Alabama USAABSTRACT Background Real‐world evidence for hypomethylating agent (HMA) + venetoclax 50 mg (VEN50) with voriconazole and posaconazole in acute myeloid leukemia (AML), is limited. Methods We evaluated outcomes of patients with newly‐diagnosed AML treated with HMA + VEN50 with either posaconazole (n = 23) or voriconazole (n = 95). Results We report that treatment with HMA + VEN50 with either azole elicits a response rate similar to that described in the VIALE‐A trial. Reducing the VEN dose to 50 mg with either strong CYP3A4 inhibitor did not compromise on the efficacy of the combination. Conclusion HMA + VEN50 with either posaconazole or voriconazole yields comparable responses to higher doses of VEN reported previously. Clinical trial registration The authors have confirmed clinical trial registration is not needed for this submission.https://doi.org/10.1002/jha2.70049acute myeloid leukemia (AML)posaconazoleVenetoclax 50 mgvoriconazole |
| spellingShingle | Kendall Diebold Devan Parker Sarah Worth Manuel Espinoza‐Gutarra Pankit Vachhani Kimo Bachiashvili Sravanti Rangaraju Razan Mohty Ravi Bhatia Omer Jamy Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia eJHaem acute myeloid leukemia (AML) posaconazole Venetoclax 50 mg voriconazole |
| title | Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia |
| title_full | Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia |
| title_fullStr | Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia |
| title_full_unstemmed | Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia |
| title_short | Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia |
| title_sort | outcomes with venetoclax 50 mg hypomethylating agents and voriconazole or posaconazole in acute myeloid leukemia |
| topic | acute myeloid leukemia (AML) posaconazole Venetoclax 50 mg voriconazole |
| url | https://doi.org/10.1002/jha2.70049 |
| work_keys_str_mv | AT kendalldiebold outcomeswithvenetoclax50mghypomethylatingagentsandvoriconazoleorposaconazoleinacutemyeloidleukemia AT devanparker outcomeswithvenetoclax50mghypomethylatingagentsandvoriconazoleorposaconazoleinacutemyeloidleukemia AT sarahworth outcomeswithvenetoclax50mghypomethylatingagentsandvoriconazoleorposaconazoleinacutemyeloidleukemia AT manuelespinozagutarra outcomeswithvenetoclax50mghypomethylatingagentsandvoriconazoleorposaconazoleinacutemyeloidleukemia AT pankitvachhani outcomeswithvenetoclax50mghypomethylatingagentsandvoriconazoleorposaconazoleinacutemyeloidleukemia AT kimobachiashvili outcomeswithvenetoclax50mghypomethylatingagentsandvoriconazoleorposaconazoleinacutemyeloidleukemia AT sravantirangaraju outcomeswithvenetoclax50mghypomethylatingagentsandvoriconazoleorposaconazoleinacutemyeloidleukemia AT razanmohty outcomeswithvenetoclax50mghypomethylatingagentsandvoriconazoleorposaconazoleinacutemyeloidleukemia AT ravibhatia outcomeswithvenetoclax50mghypomethylatingagentsandvoriconazoleorposaconazoleinacutemyeloidleukemia AT omerjamy outcomeswithvenetoclax50mghypomethylatingagentsandvoriconazoleorposaconazoleinacutemyeloidleukemia |